display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced UC (mUC) - 2nd Line (L2)
mUC - L2 - all populationmUC - L2 - PDL1 positive
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone IMvigor-211 ... IMvigor-211 ... IMvigor-211 ...
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-045 ... KEYNOTE-045 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons